E
Eric Larsen
Researcher at Tufts Medical Center
Publications - 93
Citations - 6100
Eric Larsen is an academic researcher from Tufts Medical Center. The author has contributed to research in topics: Asparaginase & Minimal residual disease. The author has an hindex of 26, co-authored 87 publications receiving 5175 citations. Previous affiliations of Eric Larsen include Tufts University.
Papers
More filters
Journal ArticleDOI
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Kathryn G. Roberts,Yongjin Li,Debbie Payne-Turner,Richard C. Harvey,Yung-Li Yang,Dehua Pei,Kelly McCastlain,Li Ding,Li Ding,Changxue Lu,Changxue Lu,Guangchun Song,Jing Ma,Jared Becksfort,Michael Rusch,S. C. Chen,John Easton,J. Cheng,Kristy Boggs,Natalia Santiago-Morales,Ilaria Iacobucci,Robert S. Fulton,Robert S. Fulton,Ji Wen,Marcus B. Valentine,Cheng Cheng,Steven W. Paugh,Meenakshi Devidas,Meenakshi Devidas,I-Ming Chen,S. Reshmi,S. Reshmi,Amy Smith,Erin Hedlund,Pankaj Gupta,Panduka Nagahawatte,Gang Wu,Xiang Chen,Donald Yergeau,Bhavin Vadodaria,Heather L. Mulder,Naomi J. Winick,Eric Larsen,William L. Carroll,William L. Carroll,Nyla A. Heerema,Andrew J. Carroll,G. Grayson,Sarah K. Tasian,Andrew S. Moore,F. Keller,Melissa Frei-Jones,J. A. Whitlock,Elizabeth A. Raetz,Deborah L. White,Timothy P. Hughes,J. M. Guidry Auvil,Malcolm A. Smith,Malcolm A. Smith,Guido Marcucci,Clara D. Bloomfield,Krzysztof Mrózek,Jessica Kohlschmidt,Jessica Kohlschmidt,Wendy Stock,Steven M. Kornblau,Marina Konopleva,Elisabeth Paietta,Ching-Hon Pui,Sima Jeha,Mary V. Relling,William E. Evans,Daniela S. Gerhard,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Elaine R. Mardis,Richard K. Wilson,Mignon L. Loh,Mignon L. Loh,James R. Downing,James R. Downing,Stephen P. Hunger,Stephen P. Hunger,Cheryl L. Willman,Cheryl L. Willman,Jinghui Zhang,Charles G. Mullighan,Charles G. Mullighan +87 more
TL;DR: Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors.
Journal ArticleDOI
PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes.
Eric Larsen,Alessandro Celi,Gary E. Gilbert,Barbara C. Furie,John K. Erban,Roberta Bonfanti,Denisa D. Wagner,Bruce Furie +7 more
TL;DR: Results indicate that PADGEM mediates adhesion of activated platelets to monocytes and neutrophils and shares not only structural but also functional homology with ELAM-1 and MEL-14, members of a new family of vascular cell adhesion molecules.
Journal ArticleDOI
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts,Ryan D. Morin,Jinghui Zhang,Martin Hirst,Yongjun Zhao,Xiaoping Su,Shann-Ching Chen,Debbie Payne-Turner,Michelle L. Churchman,Richard C. Harvey,Xiang Chen,Corynn Kasap,Chunhua Yan,Jared Becksfort,Richard Finney,David T. Teachey,Shannon L. Maude,Kane Tse,Richard A. Moore,Steven J.M. Jones,Karen Mungall,Inanc Birol,Michael N. Edmonson,Ying Hu,Kenneth E Buetow,I-Ming Chen,William L. Carroll,Lei Wei,Jing Ma,Maria Kleppe,Ross L. Levine,Guillermo Garcia-Manero,Eric Larsen,Neil P. Shah,Meenakshi Devidas,Gregory H. Reaman,Malcolm A. Smith,Steven W. Paugh,William E. Evans,Stephan A. Grupp,Sima Jeha,Ching-Hon Pui,Daniela S. Gerhard,James R. Downing,Cheryl L. Willman,Mignon L. Loh,Stephen P. Hunger,Marco A. Marra,Marco A. Marra,Charles G. Mullighan +49 more
TL;DR: Several genetic alterations that activate kinase signaling in Ph-like ALL induce transformation that is attenuated with tyrosine kinase inhibitors, suggesting the treatment outcome of these patients may be improved with targeted therapy.
Journal ArticleDOI
PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate, LNF III (CD15)
Eric Larsen,Theresa M. Palabrica,Susan A. Sajer,Gary E. Gllbert,Denisa D. Wagner,Barbara C. Furie,Bruce Furie +6 more
TL;DR: CD15, lacto-N-fucopentaose III or Lex, is a component of the PADGEM ligand on neutrophils and monocytes and is evaluated for their ability to block leukocyte-PADGem binding.
Journal ArticleDOI
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Steven E. Lipshultz,Rebecca E. Scully,Stuart R. Lipsitz,Stephen E. Sallan,Stephen E. Sallan,Lewis B. Silverman,Lewis B. Silverman,Tracie L. Miller,Elly Barry,Barbara L. Asselin,Uma H. Athale,Luis A. Clavell,Eric Larsen,Albert Moghrabi,Yvan Samson,Bruno Michon,Marshall A. Schorin,Harvey J. Cohen,Donna Neuberg,E. John Orav,Steven D. Colan +20 more
TL;DR: The long-term effect of dexrazoxane on the subclinical state of cardiac health in survivors of childhood high-risk ALL 5 years after completion of doxorubicin treatment is established.